Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naomi S Coombes

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Access Microbiology|December 19, 2024
Modelling SARS-CoV-2 infection in a human alveolus microphysiological systemTanja Šuligoj, Naomi S Coombes, Catherine Booth, et al.
Viruses|March 30, 2023
Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard ReagentsNaomi S Coombes, Kevin R Bewley, Yann Le Duff, et al.
Viruses|May 27, 2023
The Omicron Sub-Variant BA.4 Displays a Remarkable Lack of Clinical Signs in a Golden Syrian Hamster Model of SARS-CoV-2 InfectionElizabeth R Davies, Kathryn A Ryan, Kevin R Bewley, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 27, 2023
Detection of SARS-CoV-2 BA.2.86 by lateral flow devicesAbbie Bown, Angela Sweed, Matthew Catton, et al.
Viruses|March 30, 2023
SARS-CoV-2 Disease Severity in the Golden Syrian Hamster Model of Infection Is Related to the Volume of Intranasal InoculumAlastair Handley, Kathryn A Ryan, Elizabeth R Davies, et al.
Elife|September 29, 2021
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variantHelen Parry, Gokhan Tut, Rachel Bruton, et al.
Nature Protocols|April 24, 2021
Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assaysKevin R Bewley, Naomi S Coombes, Luc Gagnon, et al.
Plos Pathogens|April 4, 2023
Syrian hamster convalescence from prototype SARS-CoV-2 confers measurable protection against the attenuated disease caused by the Omicron variantKathryn A Ryan, Kevin R Bewley, Robert J Watson, et al.
Nature Communications|January 5, 2021
Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunityKathryn A Ryan, Kevin R Bewley, Susan A Fotheringham, et al.
Nature Communications|February 25, 2021
Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19Francisco J Salguero, Andrew D White, Gillian S Slack, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Access Microbiology|December 19, 2024
Modelling SARS-CoV-2 infection in a human alveolus microphysiological systemTanja Šuligoj, Naomi S Coombes, Catherine Booth, et al.
Viruses|March 30, 2023
Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard ReagentsNaomi S Coombes, Kevin R Bewley, Yann Le Duff, et al.
Viruses|May 27, 2023
The Omicron Sub-Variant BA.4 Displays a Remarkable Lack of Clinical Signs in a Golden Syrian Hamster Model of SARS-CoV-2 InfectionElizabeth R Davies, Kathryn A Ryan, Kevin R Bewley, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 27, 2023
Detection of SARS-CoV-2 BA.2.86 by lateral flow devicesAbbie Bown, Angela Sweed, Matthew Catton, et al.
Viruses|March 30, 2023
SARS-CoV-2 Disease Severity in the Golden Syrian Hamster Model of Infection Is Related to the Volume of Intranasal InoculumAlastair Handley, Kathryn A Ryan, Elizabeth R Davies, et al.
Elife|September 29, 2021
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variantHelen Parry, Gokhan Tut, Rachel Bruton, et al.
Nature Protocols|April 24, 2021
Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assaysKevin R Bewley, Naomi S Coombes, Luc Gagnon, et al.
Plos Pathogens|April 4, 2023
Syrian hamster convalescence from prototype SARS-CoV-2 confers measurable protection against the attenuated disease caused by the Omicron variantKathryn A Ryan, Kevin R Bewley, Robert J Watson, et al.
Nature Communications|January 5, 2021
Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunityKathryn A Ryan, Kevin R Bewley, Susan A Fotheringham, et al.
Nature Communications|February 25, 2021
Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19Francisco J Salguero, Andrew D White, Gillian S Slack, et al.
Pageof 1